Anthrogen

Executive Summary

Anthrogen is a U.S.-based AI research lab focused on revolutionizing biologics discovery and development through its proprietary Odyssey protein-generation engine. The engine leverages a massive 102-billion-parameter protein language model combined with massively parallel experimentation, enabling the design and validation of novel molecular machines at atomic scale. Founded in 2020 and currently in preclinical stage, the company targets applications in human and planetary health, including protein therapeutics and enzyme engineering. Anthrogen's integrated platform aims to dramatically accelerate the timeline from target identification to lead optimization, potentially outperforming traditional wet-lab methods in both speed and success rate. The company operates in the rapidly growing AI-drug discovery space and has assembled a team of experts in machine learning, synthetic biology, and protein design.

Upcoming Catalysts (preview)

• Q3 2026Series A Funding Announcement70% success
• Q4 2026Publication of In Vivo Validation Data for a Lead Program60% success
• Q2 2026Partnership with a Top 20 Pharma Company50% success